Genelabs Technologies
Get Full AccessDescription
- Genelabs is a biopharmaceutical company focused on the discovery and development of novel compounds for infectious diseases. In addition to a late-stage drug candidate for Hepatitis E partnered with GlaxoSmithKline, the company is advancing multiple partnered and proprietary compounds designed to selectively inhibit replication of the hepatitis C virus, targeting the HCV viral proteins - NS5B polymerase, NS4B, and NS5A. In January 2009 Genelabs was bought by GlaxoSmithKline.
-
Headquarters:12500 Network Blvd , San Antonio, Texas, United States
More -
Phone Number: +1 210-690-6050
-
Website: https://www.genelabs.com
-
Employees:22
-
Revenue:$10 - 50M
-
Legal Name:Genelabs Technologies
-
Genelabs Technologies's Social Media
-
Is this data correct?
-
| NAICS Code: 541713 |
Show More
Sell more in less time!
Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!
Frequently Asked Questions regarding Genelabs Technologies
-
Where are Genelabs Technologies's Headquarters?
Genelabs Technologies's Headquarters are in 12500 Network Blvd ,San Antonio,Texas,United States
-
What is Genelabs Technologies's phone number?
Genelabs Technologies's phone number is +1 210-690-6050
-
What is Genelabs Technologies's official website?
Genelabs Technologies's official website is https://www.genelabs.com
-
What is Genelabs Technologies's Revenue?
Genelabs Technologies's revenue is $10 - 50M
-
What is Genelabs Technologies's NAICS code?
Genelabs Technologies's NAICS code is 541713
-
How many employees are working in Genelabs Technologies
Genelabs Technologies has 22 employees
-
What is Genelabs Technologies's Industry?
Genelabs Technologies is in the industry of Biotechnology
-
Who is Genelabs Technologies's CEO?
Genelabs Technologies's CEO is Fred Driscoll